News for Emergent BioSolutions Stock (EBS)

EBS CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.

PRNewsWire • 04/21/21

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS

Business Wire • 04/21/21

EMERGENT BIOSOLUTIONS INVESTOR ALERT: Shareholder Lawsuit Filed

Newsfile Corp • 04/21/21

Statement on Issuance of Form FDA 483 at Emergent Bayview Facility

GlobeNewsWire • 04/21/21

FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training

Benzinga • 04/21/21

FDA Issues Scathing Report Of Baltimore Warehouse Where Johnson & Johnson Vaccines Were Ruined

Forbes • 04/21/21

FDA inspection of Emergent's COVID-19 vaccine plant identifies 'potential quality issues'

Market Watch • 04/21/21

FDA finds poor conditions at Baltimore plant that ruined millions of doses of J&J Covid vaccine

CNBC • 04/21/21

U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine

Reuters • 04/21/21

The FDA cited the vaccine plant that ruined millions of Johnson & Johnson doses for unsanitary conditions, finding "brown residue" on the walls and peeling paint

Business Insider • 04/21/21

House Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify

Benzinga • 04/21/21

EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. and Encourages Investors to Contact the Firm

Business Wire • 04/21/21

Congressional investigation launched into Emergent BioSolutions' federal vaccine contracts

CNBC • 04/20/21

Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

Zacks Investment Research • 04/20/21

Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility

Benzinga • 04/19/21

FDA asks Emergent plant to pause manufacturing while it investigates botched Covid vaccines

CNBC • 04/19/21

Emergent BioSolutions says it has agreed with FDA not to manufacture new material at Baltimore facility

Market Watch • 04/19/21

Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021

GlobeNewsWire • 04/15/21

Why Emergent BioSolutions Stock Fell Today

The Motley Fool • 04/13/21

EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. is Investigating Emergent BioSolutions, Inc. on Behalf of Emergent Stockholders and Encourages Investors to Contact the Firm

Business Wire • 04/13/21

Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)

Business Wire • 04/08/21

5 Peter Lynch Growth Stocks to Consider for 2nd Quarter

GuruFocus • 04/06/21

Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine

The Motley Fool • 04/05/21

Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production

Zacks Investment Research • 04/05/21

J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant

Zacks Investment Research • 04/05/21